drugset / Trial / NCT01582698

TBE Seropersistence up to 10 Years After First Booster in Adults

NCT01582698 ↗

Phase 4 Completed 243 enrolled Pfizer
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate TBE antibody persistence from 7 to 10 years after the first booster TBE vaccination with FSME-IMMUN 0.5ml.

Timeline

Start
2012-04
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject FSME-IMMUN Vaccine 0.5 ml Intramuscular